Completed PHASE1 INTERVENTIONAL 1-arm NCT01039155

Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy

A Phase 1 Study of CTEP 5-Azacytidine in Combination With Oxaliplatin in Patients With Advanced Cancers Relapsed or Refractory or Refractory to Any Platinum Therapy

Sponsor: National Cancer Institute (NCI)

Conditions Adult Solid Neoplasm Hematopoietic and Lymphoid Cell Neoplasm

Interventions Azacitidine Laboratory Biomarker Analysis Oxaliplatin Pharmacological Study

Updated 6 times since 2017 Last updated: Oct 5, 2015 Started: Dec 31, 2009 Primary completion: Sep 30, 2012 Completion: Jul 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Adult Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm and is currently completed. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States